<DOC>
	<DOCNO>NCT00126451</DOCNO>
	<brief_summary>This investigational study determine response rate relapsed/refractory breast , colorectal non-small cell lung cancer oral suberoylanilide hydroxamic acid ( SAHA ) , evaluate PET earlier indicator response SAHA assess response evaluation criterion solid tumour ( RECIST ) criteria evaluate safety tolerability oral suberoylanilide hydroxamic acid .</brief_summary>
	<brief_title>A Clinical Trial Oral Suberoylanilide Hydroxamic Acid ( SAHA ) Patients With Relapsed Refractory Breast , Colorectal Non-Small Cell Lung Cancer ( 0683-011 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must 18 year old confirm diagnosis breast adenocarcinoma , colorectal carcinoma nonsmall cell lung cancer Patients must relapse refractory disease follow least one chemotherapeutic treatment regimen . Has measurable , positron emission tomography ( PET ) assessable lesion Adequate blood , liver , bone marrow kidney function Has receive chemotherapy least 4 week prior entry study Agrees take adequate measure prevent pregnancy . Patient prior treatment histone deacetylase ( HDAC ) inhibitor . Patient treatment investigational agent within last 30 day . Patient active infection intravenous ( IV ) antibiotic , antiviral , antifungal medication within 2 week start study drug . Patient HIV , hepatitis B hepatitis C infection . Patient pregnant lactating . Patient allergy component study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>